Complete title: A Pilot Study of Weekly Brentuximab Vedotin or Brentuximab Vedotin Plus Nivolumab Every 3 Weeks in Patients with CD30+ Malignancies Refractory to Every 3 Week Brentuximab Vedotin
Research Study Number | 7808 |
Principal Investigator | Ajay Gopal, MD |
Phase | II |
Other eligibility criteria may apply.
Research Study Number | 7808 |
Contact | Seattle Cancer Care Alliance Intake Office |
Telephone | 800-804-8824 / 206-606-1024 |
Keywords: Lymphoma, Burkitt; Hematologic Malignancies; Leukemia; Lymphoma; Lymphoproliferative Disorders; Lymphoma, Non-Hodgkin (NHL); Waldenstrom Macroglobulinemia; Lymphoma, Mantle-Cell; Lymphoma, B-Cell; Lymphoma, T-Cell; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Follicular; Leukemia, B-Cell; Leukemia, T-Cell; Leukemia, Lymphocytic, Chronic, B-Cell
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.
Please remember:
Talk to your health care providers first before making decisions about your health care.
Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.